VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.

Cancer chemotherapy and pharmacology ·Vol. 10 ·No. 3 ·1983-00-00 ·Pages 154-7

Estapé J, Cirera L, Millá A, Doncel F

Abstract

Twenty-seven patients with histologically proved advanced breast cancer were given VP 16-213 and cyclophosphamide. Twenty-one had shown resistance to other chemotherapy schedules and six had experienced relapse during adjuvant chemotherapy. There were four complete responses (15%) and seven partial responses (26%). Median survival was 61 weeks and median duration of response was 31.4 weeks. All patients experienced gastrointestinal toxicity and 22 patients (81%) showed bone marrow toxicity. This regimen is effective in advanced breast cancer resistant to other chemotherapy regimens.

MeSH Terms

Adult Aged Breast Neoplasms/drug therapy Cyclophosphamide/administration & dosage,adverse effects Drug Evaluation Drug Synergism Drug Therapy, Combination Etoposide/administration & dosage,adverse effects Female Humans Middle Aged Neoplasm Metastasis Podophyllotoxin/analogs & derivatives Prognosis

Chemicals

Etoposide Cyclophosphamide Podophyllotoxin

Authors & Affiliations

4 authors, click to expand affiliations / ORCID

Estapé J

Cirera L

Millá A

Doncel F

References (9)

9 references, click to expand

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).
Cancer Chemother Rep. 1972 Dec;56(6):769-77 PMID: 4634038
VP 16-213 (VP 16) and cyclophosphamide in the treatment of primitive lung cancer in phase M 1.
Cancer. 1979 Jan;43(1):72-7 PMID: 761177
cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1459-73 PMID: 291480
Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast.
Cancer Treat Rev. 1976 Sep;3(3):141-74 PMID: 963686
VP-16 plus cyclophosphamide in the treatment of advanced lung cancer.
Cancer. 1983 Feb 1;51(3):385-9 PMID: 6295601
Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213.
Eur J Cancer. 1975 Sep;11(9):639-47 PMID: 1220978
Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
Cancer. 1975 Apr;35(4):1108-15 PMID: 1116104
Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.
Acta Pathol Microbiol Scand A. 1973 Sep;81(5):715-24 PMID: 4771975
Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard.
Cancer. 1976 Nov;38(5):1882-6 PMID: 991103

Article Info

Journal

Cancer chemotherapy and pharmacology

Abbr.

Cancer Chemother Pharmacol

ISSN

0344-5704

DOI

10.1007/BF00255751

Published

1983-00-00

Pages

154-7

Language

English

Region

Germany

NLM ID

7806519

Subset

External Links

PubMed source DOI: 10.1007/BF00255751 View journal details

Analysis Services

VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.

Contact

WeChat Official Account